Vise Technologies Inc. Acquires New Holdings in ACADIA Pharmaceuticals Inc. $ACAD

Vise Technologies Inc. acquired a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 14,782 shares of the biopharmaceutical company’s stock, valued at approximately $319,000.

A number of other large investors also recently added to or reduced their stakes in the company. American Century Companies Inc. boosted its holdings in ACADIA Pharmaceuticals by 1,055.8% during the 1st quarter. American Century Companies Inc. now owns 1,632,749 shares of the biopharmaceutical company’s stock valued at $27,120,000 after acquiring an additional 1,491,484 shares during the period. Nuveen LLC acquired a new position in shares of ACADIA Pharmaceuticals during the first quarter worth about $21,630,000. Vanguard Group Inc. raised its holdings in ACADIA Pharmaceuticals by 9.0% in the first quarter. Vanguard Group Inc. now owns 15,203,234 shares of the biopharmaceutical company’s stock valued at $252,526,000 after acquiring an additional 1,255,594 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in shares of ACADIA Pharmaceuticals by 73.7% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,977,432 shares of the biopharmaceutical company’s stock valued at $32,845,000 after purchasing an additional 838,728 shares in the last quarter. Finally, Jupiter Asset Management Ltd. acquired a new stake in ACADIA Pharmaceuticals in the first quarter valued at $6,761,000. 96.71% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director James M. Daly sold 30,000 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $22.37, for a total value of $671,100.00. Following the transaction, the director directly owned 4,041 shares of the company’s stock, valued at approximately $90,397.17. This trade represents a 88.13% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Mark C. Schneyer sold 3,498 shares of the business’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $23.65, for a total value of $82,727.70. Following the sale, the executive vice president directly owned 43,447 shares of the company’s stock, valued at approximately $1,027,521.55. This trade represents a 7.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 35,098 shares of company stock valued at $795,396 over the last quarter. Company insiders own 26.50% of the company’s stock.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ ACAD opened at $23.83 on Monday. The firm’s 50 day moving average price is $22.42 and its 200 day moving average price is $22.31. The firm has a market cap of $4.03 billion, a P/E ratio of 17.92, a price-to-earnings-growth ratio of 7.90 and a beta of 0.80. ACADIA Pharmaceuticals Inc. has a 1 year low of $13.40 and a 1 year high of $26.65.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.28. The business had revenue of $278.63 million during the quarter, compared to the consensus estimate of $276.52 million. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.The business’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.20 earnings per share. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on ACAD. JMP Securities raised their price objective on shares of ACADIA Pharmaceuticals from $37.00 to $38.00 and gave the stock a “market outperform” rating in a report on Thursday, August 7th. Wall Street Zen raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Mizuho raised their price objective on shares of ACADIA Pharmaceuticals from $23.00 to $24.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. JPMorgan Chase & Co. decreased their target price on shares of ACADIA Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a research report on Monday, September 29th. Finally, The Goldman Sachs Group lifted their price objective on ACADIA Pharmaceuticals from $15.00 to $17.00 and gave the stock a “sell” rating in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.94.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.